Two Treatment Regimens of Cocamide DEA Lotion for Head Lice

NCT ID: NCT02499549

Last Updated: 2015-07-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

112 participants

Study Classification

INTERVENTIONAL

Study Start Date

1999-10-31

Study Completion Date

1999-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the efficacy and safety of 10% Cocamide DEA using two treatment regimens in the eradication of head lice. To assess the ability of each treatment regimen to kill all viable ova and to assess patient acceptability of the product in use

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A previous study found that a formulation of 10% cocamide diethanolamine (DEA) aqueous lotion showed some efficacy to eliminate head louse infestation but that the treatment regimen was inadequate to kill all lice or louse eggs. This study has been designed to compare two different application regimens that have been shown effective in vitro.

A planned total of 120 patients who, following examination, are found to suffer from active head lice infestation will be recruited to the trial. The patient will be treated with 10% cocamide DEA lotion using the appropriate treatment regimen according to the randomization code from a pre-prepared listing in balanced blocks of 12.

Group 1: 10% cocamide DEA is applied directly to dry hair, the excess water evaporated off using a hair dryer and is then left for 8 hour/overnight before washing off with clean water.

Group 2: 10% cocamide DEA is applied directly to dry hair, the excess water evaporated off using a hair dryer and is then left for 2 hours before washing off with clean water. A follow up treatment is given after 7 days.

Treatments will be applied by experienced investigators throughout the study. Assessments will be made by other investigators unaware of the treatment regimen used.

After treatment (day 0), follow up assessments will be performed on days 4, 8,11 then again at day 14 after which they will leave the study. Any adverse events or side effects from the treatments will be monitored during the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pediculosis Head Louse Infestation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

10% Cocamide diethanolamine 8 hours

Cocamide DEA topical lotion applied 8 hours/overnight with drying

Group Type EXPERIMENTAL

cocamide diethanolamine

Intervention Type DRUG

10% Cocamide DEA aqueous lotion is applied directly to dry hair and is washed off with water only

10% Cocamide diethanolamine 2 hours

Cocamide DEA topical lotion applied 2 hours with drying, repeated after 7 days

Group Type EXPERIMENTAL

cocamide diethanolamine

Intervention Type DRUG

10% Cocamide DEA aqueous lotion is applied directly to dry hair and is washed off with water only

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cocamide diethanolamine

10% Cocamide DEA aqueous lotion is applied directly to dry hair and is washed off with water only

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

lauramine diethanolamine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients over the age of 4 who are found to have a head louse infection.
* Patients who give written informed consent and, if the patient is under 16 years of age, whose guardian gives written informed consent to participate in the study.
* Available for the duration of study i.e. 15 days.

Exclusion Criteria

* Patients with a known sensitivity to paraben preservatives.
* Patients who have been treated with other head lice products within the last 2 weeks.
* Patients who have undergone a course of antibiotic treatment within the last 4 weeks.
* Patients who have any persistent skin disorder of the scalp (i.e. eczema, chronic dermatitis, psoriasis).
* Patients whose hair has been bleached, colour treated or permed within the last 4 weeks.
* Patients who have participated in another clinical trial within 1 month prior to entry to this study.
* Patients who have already participated in this clinical trial.
Minimum Eligible Age

4 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Riemann a/s

UNKNOWN

Sponsor Role collaborator

Medical Entomology Centre

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ian F Burgess

Role: PRINCIPAL_INVESTIGATOR

Medical Entomology Centre

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CTRL02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.